Citations

Clear

941 citation(s) found for "Tefferi, A".

Mutation profiling of chronic myeloproliferative neoplasms: improving clinical-molecular prognostic models
Loscocco, Giuseppe Gaetano , Gangat, Naseema , Tefferi, Ayalew , Loscocco, Giuseppe Gaetano , Guglielmelli, Paola , Vannucchi, Alessandro M.

Mayo Clinic

Expert Review of Molecular Diagnostics | October 11, 2025 | Volume: 25 | Issue: 11 | Pages: 775-792

10.1080/14737159.2025.2573466 | PMID 41074259 Get It

Prevalence of Concurrent (Double‐Positive) JAK2 , CALR , or MPL Mutations and Corresponding Clinicopathologic Featu
He, Rong , Ollila, Paul L., Zhang, Xi , Ji, Yuan , Rangan, Aruna , Gangat, Naseema , Chen, Dong , Tefferi, Ayalew , Viswanatha, David S., Yuan, Ji , Chen, Dong , Tefferi, Ayalew , Shi, Min

Mayo Clinic

American Journal of Hematology | October 4, 2025 | Volume: 100 | Issue: 12 | Pages: 2431-2435

10.1002/ajh.70098 | PMID 41045031 Get It

Validation of BLAST and BLAST ‐Mol Risk Models in Chronic Myelomonocytic Leukemia: Mayo–Humanitas Collaborative Project Involving 1101 Patients
Fathima, Saubia , Alsugair, Ali, Yousuf, Muhammad , Faldu, Priyansh, Csizmar, Clifford M. , Nakhleh, Merry , Mangaonkar, Abhishek A. , Pardanani, Animesh , Lanino, Luca , Campagna, Alessia , Reichard, Kaaren K. , He, Rong , Gangat, Naseema , Patnaik, Mrinal M. , Tefferi, Ayalew , Csizmar, Clifford , He, Rong , Gangat, Naseema , Patnaik, Mrinal , Tefferi, Ayalew , Fathima, Saubia , Campagna, Alessia , Lanino, Luca , Maggioni, Giulia , Della Porta, Matteo Giovanni

Mayo Clinic

American Journal of Hematology | September 25, 2025 | Volume: 100 | Issue: 12 | Pages: 2426-2430

10.1002/ajh.70080 | PMID 40996347 Get It

Myeloproliferative Neoplasms‐Unclassifiable ( MPN ‐U): A Carefully Curated Series of 30 Mayo Clinic Patients
Abdelaziz, Rania M. , Faldu, Priyansh, Fathima, Saubia, Zepeda‐Mendoza, Cinthya , Pardanani, Animesh , He, Rong , Reichard, Kaaren K. , Gangat, Naseema , Tefferi, Ayalew , Fathima, Saubia , Zepeda-Mendoza, Cinthya J , Gangat, Naseema , Tefferi, Ayalew , Fathima, Saubia , Abdelaziz, Rania , Orazi, Attilio

Mayo Clinic

American Journal of Hematology | September 23, 2025 | Volume: 100 | Issue: 12 | Pages: 2404-2410

10.1002/ajh.70085 | PMID 40985236 Get It

Distinct clinical, laboratory, molecular, and pathologic features of systemic mastocytosis involving the gastrointestinal tract
Chiu, April , Viswanatha, David S., He, Rong , Reichard, Kaaren K. , Tefferi, Ayalew, Pardanani, Animesh , Chen, Dong , Majerus, Julie A. , Chen, Dong , Tefferi, Ayalew

Mayo Clinic

Am J Clin Pathol | September 9, 2025 | Volume: 164 | Issue: 6 | Pages: 879-889

10.1093/ajcp/aqaf112 | PMID 41293991 Get It

Abstract Objective Gastrointestinal (GI) symptoms are common in systemic mastocytosis (SM). We hereby report the clinicopathologic and molecular features of GI mastocytosis. Methods The study includes 104 patients with suspected SM. Of 258 GI biopsy ­specimens, 33 (20 patients, 19%) were mastocytosis-positive, with 19 (16 patients) initially missed. Results Tryptase (n = 29) was weakly positive/negative in two-thirds of the mastocytosis-positive GI biopsy specimens. Additional immunohistochemistry (n = 23) showed positive mast cell expression for CD30 (n = 2), CD123 (n = 7), and PD-L1 (n = 12), as well as increased PD-1–positive cells (n = 4). Sixty patients had positive bone marrow (BM) for SM (SM-BM+), including 19 with positive GI biopsy specimens (SM-GI+). Almost all (43/44) SM-BM– patients were SM-GI–. The SM-GI vs SM-BM status showed high positive predictive value (95%) and specificity (98%). Patients with SM with mastocytosis-positive vs mastocytosis-negative GI biopsy specimens had higher serum tryptase levels (P = .04). KIT D816V mutation was detected in 7 of 13 and 12 of 13 mastocytosis-positive GI biopsy specimens using allele-specific polymerase chain reaction and droplet digital polymerase chain reaction (ddPCR), respectively. Conclusions GI mastocytosis is highly predictive of SM in BM; however, most SM-BM+ patients are SM-GI–. The SM-BM– patients are very unlikely to be SM-GI+. Because GI neoplastic mast cells are often tryptase negative, diagnostic evaluation should include CD117 and CD25 immunohistochemistry, as well as KIT D816V mutation analysis by ddPCR as needed.
Triple A Plus ( AAA + ) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients
Tefferi, Ayalew , Loscocco, Giuseppe Gaetano , Rokach, Lior , Tadmor, Tamar , Faldu, Priyansh, Melamed, Guy , Alapi, Hilel, Abdelmagid, Maymona, Abdelaziz, Rania M., Yousuf, Muhammad , Nakhleh, Merry , Pardanani, Animesh , Begna, Kebede H. , Patnaik, Mrinal M. , Barbui, Tiziano , Reichard, Kaaren K. , He, Rong , Gangat, Naseema , Loscocco, Giuseppe Gaetano , Patnaik, Mrinal , Szuber, Natasha , He, Rong , Guglielmelli, Paola , Gangat, Naseema , Vannucchi, Alessandro M , Abdelaziz, Rania M., Szuber, Natasha , Carobbio, Alessandra , Guglielmelli, Paola , Vannucchi, Alessandro M.

Mayo Clinic

American Journal of Hematology | September 3, 2025 | Volume: 100 | Issue: 11 | Pages: 2017-2027

10.1002/ajh.70065 | PMID 40899793 Get It

ABSTRACT Survival prediction models in essential thrombocythemia (ET) include the International Prognostic Scoring System (IPSET) and the more recently introduced triple‐A (AAA) prognostic score. The latter enlists age and absolute neutrophil (ANC) and lymphocyte (ALC) counts as risk variables. In the current study, a Mayo Clinic discovery cohort of 658 patients with ET was used to identify AAA‐independent risk variables. Accordingly, multivariable analysis‐derived HRs (95% CI) were 15.7 (8.4–29.5) for age > 70 years (8 points); 4.2 (2.3–7.5) for age 50 to 70 years (2 points); 1.8 (1.2–2.5) for ANC ≥ 8 × 10 9 /L (1 point); 1.4 (1.03–1.9) for ALC < 1.7 × 10 9 /L (1 point); 1.8 (1.2–2.6) for absolute monocyte count (AMC) ≥ 0.5 × 10 9 /L (1 point); 1.8 (1.2–2.3) for male sex (1 point); 1.8 (1.3–2.4) for arterial hypertension (1 point); and 1.6 (1.2–2.3) for arterial thrombosis (1 point). HR‐weighted scoring enabled a 4‐tiered risk classification: ultra‐low (0–1 points; N = 94; median survival 42.7 years), low (2–4 points; N = 297; 23 years), intermediate (5 points; N = 66; 17.3 years), and high (6–14 points; N = 201; 10.8 years). Time‐dependent predictive performance at 20/25 years favored AAA + (AUC 0.92/0.91) vs. AAA (0.86/0.86) vs. IPSET (0.81/0.84). The AAA + risk model was subsequently validated by two external cohorts from Israel ( N = 5968) and Italy ( N = 682). In the cohort from Israel, disease‐specific mortality was assessed by comparing observed survival to an age‐ and sex‐matched reference population, which suggested near‐normal life expectancy in ultra‐low risk patients. The current study highlights host‐related factors as the primary determinants of longevity in ET and provides a composite risk score (AAA + ) that is based on complete blood count‐derived parameters and host‐related factors. Predictive performance of the new model was shown to be superior to that of IPSET and AAA.
A Clinically Applicable Model Using Blood Counts to Support the Diagnosis of Prefibrotic Myelofibrosis Versus Essential Thrombocythemia
Barbui, Tiziano , Thiele, Jürgen, Kvasnicka, H. M. , Gisslinger, Heinz , Vannucchi, Alessandro M. , Orazi, Attilio , Tefferi, Ayalew , Gisslinger, Heinz , Vannucchi, Alessandro M , Orazi, Attilio , Tefferi, Ayalew , Ghirardi, Arianna , Gianelli, Umberto , Arber, Daniel A.

Mayo Clinic

American Journal of Hematology | July 26, 2025 | Volume: 100 | Issue: 10 | Pages: 1772-1778

10.1002/ajh.70017 | PMID 40716107 Get It

ABSTRACT This study aimed to distinguish between essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (pre‐PMF) using routine blood tests, with a focus on white blood cell (WBC) and platelet (PLT) levels. We evaluated the predicted probability of a pre‐PMF diagnosis based on the interaction between WBC and PLT levels using data from a logistic regression model involving 891 patients with ET and 180 patients with pre‐PMF. Patients were divided into four groups based on whether their WBC and PLT values were below or above the respective thresholds of 8.85 × 10 9 /L and 793 × 10 9 /L. The results showed that patients with low levels of both WBCs and PLTs had the lowest predicted probability of pre‐PMF (6%), indicating a profile more typical of ET. When either WBC or PLT levels were elevated, the probability increased to approximately 18%–19%, indicating a potential shift toward pre‐PMF features. Notably, patients with elevated levels of both WBCs and PLTs had the highest probability of a pre‐PMF diagnosis (26%), which was more than four times higher than that of the low–low group. The association between combined WBC/PLT levels and a pre‐PMF diagnosis remained significant ( p < 0.001), even when adjusting for serum lactate dehydrogenase (LDH) and splenomegaly. These findings suggest that elevated WBC and PLT levels together can serve as a practical and accessible diagnostic tool for supporting the differential diagnosis of ET or pre‐PMF in cases of uncertainty, and for deferring bone marrow biopsy in cases of early disease presenting with isolated thrombocytosis.
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia
Montalban‐Bravo, Guillermo , Loghavi, Sanam , Li, Ziyi , Chien, Kelly S. , Kanagal‐Shamanna, Rashmi , Natu, Anuya , Gurney, Mark E. , Bazinet, Alexandre , Sasaki, Koji , Kadia, Tapan M. , Ravandi, Farhad, Pemmaraju, Naveen , Finke, Christy M. , Al‐Kali, Aref , Gangat, Naseema , Mangaonkar, Abhishek A. , Bueso‐Ramos, Carlos E. , Tefferi, Ayalew, Kantarjian, H., Garcia‐Manero, Guillermo , Patnaik, Mrinal M. , Kantarjian, Hagop M. , Chien, Kelly , Gurney, Mark , Sasaki, Koji , DiNardo, Courtney , Daver, Naval , Short, Nicholas , Pemmaraju, Naveen , Issa, Ghayas , Al-Kali, Aref , Csizmar, Clifford , Gangat, Naseema , Patnaik, Mrinal , Loghavi, Sanam , Kanagal-Shamanna, Rashmi , Kantarjian, Hagop , Bataller, Alex , Hammond, Danielle , Borthakur, Gautam , Swaminathan, Mahesh , DiNardo, Courtney D. , Ravandi, Farhad , Daver, Naval , Short, Nicholas J. , Lasho, Terra L. , Csizmar, Clifford M. , Alkhateeb, Hassan B. , Tefferi, Ayalew

Mayo Clinic

Blood Advances | July 11, 2025 | Volume: 9 | Issue: 19 | Pages: 5105-5117

10.1182/bloodadvances.2025016529 | PMID 40644618 Get It

Abstract RAS pathway (RASp) mutations induce proliferative features, and promote transformation in chronic myelomonocytic leukemia (CMML). However, the unique clonal landscape and hierarchy of distinct RASp mutations remain unexplored. To characterize the landscape, architecture, and implications of unique RASp mutations in CMML, we evaluated a cohort of 814 patients with CMML. We identified 461 RASp mutations among 342 patients (42%). N/KRAS and CBL mutations were the most common, frequently involved the P-loop or RING domains, respectively, and frequently appeared as dominant events (63% and 65%, respectively). BRAF, NF1, and PTPN11 mutations spanned throughout the gene structure, and frequently appeared as subclonal events (75%, 64%, and 59%, respectively). CBL mutations frequently occurred in codominance with SRSF2 and multihit TET2, and were enriched for KIT mutations. PTPN11 mutations more frequently co-occurred with SETBP1 and DNMT3A mutations, and were infrequently codominant with TET2 or ASXL1. RASp mutations predicted for shorter overall survival (hazard ratio [HR], 1.55; 95% confidence interval [CI], 1.15-2.07; P = .0075) and leukemia-free survival (LFS; HR, 1.67; 95% CI, 1.26-2.20; P = .0011), influenced outcomes of myelodysplastic and TET2 mutant CMML, and cooperated with IDH2 and RUNX1 mutations to induce shorter LFS. These data set the bases for refined genomic classifications of CMML, and underscore the need to develop RAS-directed therapies for patients with CMML.